Skip to main content

New Drug Approvals 2012 - Pt. IX - Florbetapir F 18 (AmyvidTM)






ATC code: V09AX05 (incomplete)


On April 6th, FDA approved Amyvid (Florbetapir F 18), a radiolabeled intravenous imaging agent for the differential diagnosis of Alzheimer's Disease.

Alzheimer's Disease (OMIM 104300, MeSH D000544) is a non-treatable, progressively worsening and fatal disease and the main cause of dementia.
Most commonly affecting the elderly (>65y), it correlates with the growing deposits of aggregating beta amyloid (UniProt P05067) fibrils in the brain, eventually physically destroying it, and abnormal aggregation of the tau protein (UniProt P10636), a microtubule-associated protein inside neurons.
Early symptoms of Alzheimer's include impairment of short term memory, advanced ones, irritability, confusion, aggression, mood swings, and long term memory loss, amongst others.

Diagnosis of Alzheimer's is complicated by overlap of symptoms with other cognitive diseases, and "normal" signs of ageing; sometimes, only brain autopsy (necessarily posthumous) can confirm its presence, while, conversely, patients displaying typical Alzheimer's symptoms sometimes don't show its physiological manifestation. Differential diagnostic techniques include detection of (amongst other biomarkers) amyloid or tau proteins in the spinal fluid, and brain imaging using Positron Emission Tomography (PET), with or without contrast enhancing agents, i.e. radionuclides. A drawback of an early such compound, Pittsburgh compound B (PiB, ChEMBL ID CHEMBL207456, PubChem 2826731), is the short half life (~20 minutes) of the carbon isotope (11C) included. Florbetapir, on the other hand, has a radioactive fluorine isotope (18F) with a half life of ~2 hours, improving its handling and signal strength.

It has to be noted that the presence of plaques, e.g. visualized by PET, and potentially aided by Florbetapir, does not necessarily and sufficiently indicate Alzheimer's; plaques may be present in patients with other neurological disorders, or elderly people with normal cognition. However the absence of significant plaques may rule out the possibility of a patient suffering from Alzheimer's.


Florbetapir (ChEMBL ID CHEMBL1774461, PubChem 24822371) is a radiocompound with molecular weight 360.4 Da, ALogP 3.14, 1 hydrogen bond donor, 4 hydrogen bond acceptors, and thus fully rule of five compliant. It possesses a radioactive isotope of fluorine, 18F, and a C=C double bond in trans / E configuration.
Its systematic (IUPAC) name is 4-[(E)-2-[6-[2-[2-(2-fluoranylethoxy)ethoxy]ethoxy]pyridin-3-yl]ethenyl]-N-methylaniline, Canonical SMILES CNc1ccc(\C=C\c2ccc(OCCOCCOCC[18F])nc2)cc1, Standard InChI=1S/C20H25FN2O3/c1-22-19-7-4-17(5-8-19)2-3-18-6-9-20(23-16-18)26-15-14-25-13-12-24-11-10-21/h2-9,16,22H,10-15H2,1H3/b3-2+/i21-1.

After injection of Amyvid as a single recommended dose of 370 MBq, the agent passes the blood brain barrier and accumulates at amyloid plaques in the patient's brain. 30 to 50 minutes post injection, a 10 minute PET image is acquired.

It is unknown whether Amyvid affects reproductive capacity or causes fetal harm, or whether it is secreted in human milk, but it is not recommended to be used in the respective population. The agent is not indicated for use in pediatric patients. Majority of clinical studies subjects being elderly, no overall differences in safety or effectiveness between them and younger subjects were observed. Because of the agent being radioactive, special precautions have to be taken retrieving, transporting, and administering the agent. The radiation absorbed dose from a single Amyvid dose is 7 mSv in an adult and thus comparable to a chest CT scan, or about twice the normal yearly background dose.
Notable adverse reactions include headache (<2% of patients), musculoskeletal pain, fatigue, nausea (<1%), and anxiety, back pain, increased blood pressure, claustrophobia, feeling cold, insomnia, and neck pain (<0.5%). In early 2011, FDA recommended against approval of Florbetapir, unless structured training programmes for PET readers using Florbetapir would be provided; latest clinical trials of Florbetapir include data from readers either trained manually, or electronically, both proving to be effective.

Amyvid has been developed by Eli Lilly and Company, and Avid Radiopharmaceuticals Inc., its wholly owned subsidiary, and is marketed by Lilly.

The full prescribing information can be found here.



Comments

Popular posts from this blog

RDKit, C++ and Jupyter Notebook

Fancy playing with RDKit C++ API without needing to set up a C++ project and compile it? But wait... isn't C++ a compiled programming language? How this can be even possible?

Thanks to Cling (CERN's C++ interpreter) and xeus-cling jupyter kernel is possible to use C++ as an intepreted language inside a jupyter notebook!

We prepared a simple notebook showing few examples of RDKit functionalities and a docker image in case you want to run it.

With the single requirement of docker being installed in your computer you'll be able to easily run the examples following the three steps below:
docker pull eloyfelix/rdkit_jupyter_clingdocker run -d -p 9999:9999 eloyfelix/rdkit_jupyter_clingopen http://localhost:9999/notebooks/rdkit_cling.ipynb in a browser


ChEMBL 25 and new web interface released

We are pleased to announce the release of ChEMBL 25 and our new web interface. This version of the database, prepared on 10/12/2018 contains:

2,335,417 compound records1,879,206 compounds (of which 1,870,461 have mol files)15,504,603 activities1,125,387 assays12,482 targets72,271 documents

Data can be downloaded from the ChEMBL ftp site: ftp://ftp.ebi.ac.uk/pub/databases/chembl/ChEMBLdb/releases/chembl_25

Please see ChEMBL_25 release notes for full details of all changes in this release: ftp://ftp.ebi.ac.uk/pub/databases/chembl/ChEMBLdb/releases/chembl_25/chembl_25_release_notes.txt


DATA CHANGES SINCE THE LAST RELEASE

# Deposited Data Sets:

Kuster Lab Chemical Proteomics Drug Profiling (src_id = 48, Document ChEMBL_ID = CHEMBL3991601):
Data have been included from the publication: The target landscape of clinical kinase drugs. Klaeger S, Heinzlmeir S and Wilhelm M et al (2017), Science, 358-6367 (https://doi.org/10.1126/science.aan4368)

# In Vivo Assay Classification:

A classification…

FPSim2, a simple Python3 molecular similarity tool

FPSim2 is a new tool for fast similarity search on big compound datasets (>100 million) being developed at ChEMBL. We started developing it as we needed a Python3 library able to run either in memory or out-of-core fast similarity searches on such dataset sizes.

It's written in Python/Cython and features:
A fast population count algorithm (builtin-popcnt-unrolled) from https://github.com/WojciechMula/sse-popcount using SIMD instructions.Bounds for sub-linear speed-ups from 10.1021/ci600358fA compressed file format with optimised read speed based in PyTables and BLOSCUse of multiple cores in a single search In memory and on disk search modesSimple and easy to use
Source code is available on github and Conda packages are also available for either mac or linux. To install it type:

conda install rdkit -c rdkitconda install fpsim2 -c efelix
Try it with docker (much better performance than binder):

    docker pull eloyfelix/fpsim2    docker run -p 9999:9999 eloyfelix/fpsim2    open htt…

2019 and ChEMBL – News, jobs and birthdays

Happy New Year from the ChEMBL Group to all our users and collaborators. 
Firstly, do you want a new challenge in 2019?  If so, we have a position for a bioinformatician in the ChEMBL Team to develop pipelines for identifying links between therapeutic targets, drugs and diseases.  You will be based in the ChEMBL team but also work in collaboration with the exciting Open Targets initiative.  More details can be found here(closing date 24thJanuary). 
In case you missed it, we published a paper at the end of last on the latest developments of the ChEMBL database “ChEMBL: towards direct deposition of bioassay data”. You can read it here.  Highlights include bioactivity data from patents, human pharmacokinetic data from prescribing information, deposited data from neglected disease screening and data from the IMI funded K4DD project.  We have also added a lot of new annotations on the therapeutic targets and indications for clinical candidates and marketed drugs to ChEMBL.  Importantly we ha…

ChEMBL_27 SARS-CoV-2 release

The COVID-19 pandemic has resulted in an unprecedented effort across the global scientific community. Drug discovery groups are contributing in several ways, including the screening of compounds to identify those with potential anti-SARS-CoV-2 activity. When the compounds being assayed are marketed drugs or compounds in clinical development then this may identify potential repurposing opportunities (though there are many other factors to consider including safety and PK/PD considerations; see for example https://www.medrxiv.org/content/10.1101/2020.04.16.20068379v1.full.pdf+html). The results from such compound screening can also help inform and drive our understanding of the complex interplay between virus and host at different stages of infection.
Several large-scale drug screening studies have now been described and made available as pre-prints or as peer-reviewed publications. The ChEMBL team has been following these developments with significant interest, and as a contribution t…